Preclinical Evidence for the Use of Oral Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone Regenerative Therapy: A Systematic Review
- Allinson Olaechea,
- Karim Benabdellah,
- ,
- Sara Gómez-Melero,
- ,
- Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO),
- Instituto Biosanitario Ibs Granada,
- Pfizer-Universidad de Granada-Junta de Andalucía,
- ,
- Maimonides Biomedical research Institute of Cordoba (IMIBIC),
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 791-800 (10 pages)Journal (Volume, Issue Number)
Stem cells translational medicine (Volume 12, Issue 12)Publication milestones
- Published - 12/2023
Publication status
ISSN
2157-6564Publication IDs
- Scopus: 85180371602
- PubMed: 37715961
Abstract
The development of extracellular vesicles (EVs) therapies has revolutionized personalized medicine, opening up new possibilities for treatment. EVs have emerged as a promising therapeutic tool within this field due to their crucial role in intercellular communication across various cell types and organisms. This systematic review aims to evaluate the therapeutic potential of oral mesenchymal stem cell (MSC)-derived EVs for bone regeneration, specifically focusing on findings from preclinical models. Sixteen articles meeting the inclusion criteria were selected following document analysis. The biological effects of oral MSC-derived EVs predominantly involve the upregulation of proteins associated with angiogenesis, and inflammation resolution, alongside the downregulation of proinflammatory cytokines. Moreover, these therapeutic agents have been found to contain a significant quantity of different molecules (proteins, lipids, DNA, microRNAs, etc) further contributing to their modulatory potential. The findings from this systematic review underscore that oral MSC-derived EVs, irrespective of their specific population, have the ability to enhance the osteogenic repair response in maxillary bone or periodontal defects. In summary, this systematic review highlights the promising potential of oral MSC-derived EVs for bone regeneration based on evidence from preclinical models. The comprehensive assessment of their biological effects and the presence of microRNAs underscores their therapeutic significance. These findings support the utilization of oral MSC-derived EVs in enhancing the osteogenic repair response in various maxillary bone or periodontal defects, providing insights into the mechanisms involved and potential therapeutic applications in the field of personalized medicine.
